Trifolium Bioscience Limited (Trifolium Bio-B) submitted the latest Securities Monthly Return to Hong Kong Exchanges and Clearing Limited on October 7, 2024, reporting the shareholding changes as of September 30, 2024. The report shows that the company's statutory/registered share capital and issued shares (excluding treasury shares) remained unchanged during the reporting period, at 2,000,000,000 ordinary shares with a par value of $0.0001 per share, total statutory/registered share capital of $200,000, and total issued shares of 1,297,048,929 shares. Additionally, in the company's share options scheme, the number of share options under the Pre-IPO Share Option Scheme and Post-IPO Share Option Scheme are 1,848,817 shares and 30,091,988 shares, respectively. There were no new share options exercised during the month, and no share options lapsed or were cancelled. Overall, Trifolium Bio-B maintained a stable share structure in that month.

Trifolium Bioscience Limited (Trifolium Bio-B) submitted the latest Securities Monthly Return to Hong Kong Exchanges and Clearing Limited on October 7, 2024, reporting the shareholding changes as of September 30, 2024. The report shows that the company's statutory/registered share capital and issued shares (excluding treasury shares) remained unchanged during the reporting period, at 2,000,000,000 ordinary shares with a par value of $0.0001 per share, total statutory/registered share capital of $200,000, and total issued shares of 1,297,048,929 shares. Additionally, in the company's share options scheme, the number of share options under the Pre-IPO Share Option Scheme and Post-IPO Share Option Scheme are 1,848,817 shares and 30,091,988 shares, respectively. There were no new share options exercised during the month, and no share options lapsed or were cancelled. Overall, Trifolium Bio-B maintained a stable share structure in that month.